AmpC -lactamases are cephalosporinases that hydrolyze cephamycins as well as other extended-spectrum cephalosporins and are poorly inhibited by clavulanic acid. Although reported with increasing frequency, the true rate of occurrence of AmpC -lactamases in different organisms, including members of Enterobacteriaceae, remains unknown. The present study was designed to determine the occurrence of AmpC enzyme-harbouring Gram-negative clinical isolates in a tertiary care hospital in Pondicherry state, South India. A total of 235 Gram negative clinical isolates were tested for resistance to cefoxitin, third generation cephalosporin (3GC) antibiotics, ampicillin, amikacin, co-trimoxazole, gentamicin, meropenem and tetracycline by disc diffusion method. Isolates found resistant to 3GC and cefoxitin were tested for the production of AmpC -lactamases by three dimensional extraction method and AmpC disc method.
INTRODUCTION
The predominant mechanism for resistance to -lactam antibiotics in Gram-negative bacteria is by the synthesis oflactamases (23) . Among the -lactamases the production of ESBLs and AmpC -lactamases are the most common (10) .
AmpC -lactamases are class C or group I cephalosporinases that confer resistance to a wide variety of -lactam antibiotics including alpha methoxy -lactams such as cefoxitin, narrow and broad spectrum cephalosporins, aztreonam, and are poorly inhibited by -lactamase inhibitors such as clavulanic acid (8) .
Chromosome-mediated AmpC -lactamases have been -lactamase by mutation is probably responsible for the resistance in these organisms (13, 18) . In most genera of the family Enterobacteriaceae, AmpC is inducible (8) . Unlike chromosome-mediated AmpC, plasmid-encoded AmpC enzymes are almost always expressed constitutively (18) .Many plasmid-mediated AmpC enzymes, such as CMY-type -lactamases, have been found in bacterial species that naturally lack a chromosomal AmpC -lactamase, such as Klebsiella pneumoniae, Proteus mirabilis, and Salmonella spp.
It is believed that such -lactamases arose through the transfer of chromosomal AmpC genes onto plasmids. Plasmidmediated inducible -lactamases are extremely rare (11) .
Several epidemiological studies have shown that AmpC enzyme producing bacteria are recovered from hospitalized patients after several days of admission to the hospital.
Affected patients have often had prolonged stay. A majority of patients had been treated with -lactam antibiotics including cefoxitin (16) . Although it has been over a decade since plasmid-mediated AmpC -lactamases were discovered, most clinical laboratories and physicians remain unaware of their clinical importance (2) . As a result, organisms producing these types of -lactamases often go undetected and therefore have been responsible for several nosocomial outbreaks (18) .
Without accurate laboratory detection and reporting of such resistant phenotypes and strains producing plasmid-mediated AmpC, treatment of Gram negative infection may remain suboptimal.
There is a paucity of information on the documentation of AmpC -lactamases among Gram negative isolates this region. This is due in part to the lack of standard guidelines for detecting AmpC-producing isolates. Since, the detection of organisms producing these -lactamases is thus important; a prospective study was undertaken to determine the occurrence of AmpC -lactamases in Gram negative clinical isolates at this centre. biochemically by the standard methods (14) and were stored at 4°C in 0.2% semisolid agar until used.
MATERIALS AND METHODS

Patients and bacterial strains
Antimicrobial susceptibility testing
The antibiogram of the isolates were determined by the aerogenes were found to harbour AmpC enzymes (24, 19) . In the present study, 22% of AmpC producers were found to be susceptible to cefoxitin. AmpC production in these isolates could be due a mechanism similar to that of ESBL producing organism that appear susceptible to ceftazidime by the disc diffusion method. They may also have MIC of cefoxitin <2 g/ml, which was not tested. This finding was similar to a previous study, which reported 39% of cefoxitin susceptibility in AmpC producers (15) .
RESULTS
Antimicrobial susceptibility testing
Cefoxitin resistance in AmpC non-producers could be due to some other resistance mechanism such as, lack of permeation of porins (12) . 
